Objective
To review the 10-year clinical experience of a single institution's adult l
ung transplant program.
Methods
Since July 1988, 450 lung transplants have been performed in 443 patients.
Recipient diagnoses included emphysema in 229 patients, cystic fibrosis in
70 patients, pulmonary fibrosis in 48 patients, pulmonary hypertension in 4
9 patients, and miscellaneous end-stage lung diseases in 47 patients. Singl
e-lung transplant was performed in 157 cases, bilateral sequential lung tra
nsplant in 283 cases, en bloc double-lung transplant in 8 cases, and heart-
lung transplant in 2 cases. Graft lungs were obtained from local donors in
24% of cases and from distant donors in 76% of cases. Ideal donors were use
d in 74% of cases; in 26%, the donor was classified as marginal based on ob
jective criteria.
Results
Four hundred six (91.6%) lung transplant recipients survived to hospital di
scharge. There were 37 hospital deaths from cardiac events (n = 8), primary
graft failure (n = 8), sepsis (n = 6), anastomotic dehiscence (n = 6), and
other causes (n = 9). A diagnosis of chronic rejection (bronchiolitis obli
terans syndrome [BOS]) was made in 191 patients (42.5%). BOS has not been i
mproved by any specific therapy, Rates of freedom from BOS at 1, 3, and 5 y
ears after the transplant are 82%, 42%, and 25%. One-, 3-, and 5-year actua
rial survival rate for the entire group are 83%, 70%, and 54%. There is no
statistical difference in survival according to diagnosis or type of lung t
ransplant. Recipient waiting time was 116 days in the first 90 patients and
634 days in the most recent 90 patients.
Conclusions
Lung transplantation offers patients with end-stage lung disease acceptable
prospects for 5-year survival. Chronic rejection and long waiting lists fo
r donor lungs continue to be major problems facing lung transplant programs
. The use of marginal and distant donors is a successful strategy in improv
ing donor availability.